Cited by 2,077Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

The DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index.

Epidemiology and risk profile of heart failure

Open access

Bui, Anh L., Horwich, Tamara B., Fonarow, Gregg C.·2011·Nature Reviews Cardiology

DOI 10.1038/nrcardio.2010.165PMC PMC3033496

Open this paper in CoChat — free account

Abstract

Heart failure (HF) is a major public health issue, with a prevalence of over 5.8 million in the USA, and over 23 million worldwide, and rising. The lifetime risk of developing HF is one in five. Although promising evidence shows that the age-adjusted incidence of HF may have plateaued, HF still carries substantial morbidity and mortality, with 5-year mortality that rival those of many cancers. HF represents a considerable burden to the health-care system, responsible for costs of more than $39 billion annually in the USA alone, and high rates of hospitalizations, readmissions, and outpatient visits. HF is not a single entity, but a clinical syndrome that may have different characteristics depending on age, sex, race or ethnicity, left ventricular ejection fraction (LVEF) status, and HF etiology. Furthermore, pathophysiological differences are observed among patients diagnosed with HF and reduced LVEF compared with HF and preserved LVEF, which are beginning to be better appreciated in epidemiological studies. A number of risk factors, such as ischemic heart disease, hypertension, smoking, obesity, and diabetes, among others, have been identified that both predict the incidence of HF as well as its severity. In this Review, we discuss key features of the epidemiology and risk profile of HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrcardio.2010.165

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,824
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
Rehospitalizations among Patients in the Medicare Fee-for-Service Program
Jencks, S. F., Williams, M. V., & Coleman, E. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0803563 · Cited by 5,164
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209 · cited 1×
“HF and preserved LVEF now represents >50% of HF cases and can have outcomes as poor as those associated with HF and reduced LVEF, but it does not yet have a proven effective management strategy”
Background
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,137
Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
Swedberg, K. B., & KJEKSHUS, J. K. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652

Show all 144 references

Research works printed but not linked: 1

Gordis, L. Epidemiology 37–84 (Elsevier/Saunders, Philadelphia, 2009).

Sorted by citations

Items 401–500 of 1,002

Os custos da insuficiência cardíaca em Portugal e a sua evolução previsível com o envelhecimento da população
Gouveia, M. R. D. A., Ascenção, R. M. S. E. S., Fiorentino, F., da Costa, J. N. M. P. G., Broeiro, P., da Fonseca, M. C. F. G., & Borges, M. (2020) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.09.006 · Cited by 43
Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs
Biermann, J., Neumann, T., Angermann, C. E., Erbel, R. M., Maisch, B., Pittrow, D. B., Regitz‐Zagrosek, V., Scheffold, T., Wachter, R., Gelbrich, G., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.099 · Cited by 43
“Each year, about 600,000 new cases are diagnosed only in Western countries, while more than 20 million people suffer from CHF worldwide [3–5].”
Background
Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways
Zhou, H., Yuan, Y., Liu, Y., Deng, W., Zong, J., Bian, Z., Dai, J., & Tang, Q. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1598 · Cited by 43
“Although hypertrophy is an adaptive process that initially maintains cardiac output, sustained hypertrophy ultimately leads to heart failure, which is the leading cause of morbidity and mortality worldwide (1,2).”
Effect of a self-care educational intervention to improve self-care adherence among patients with chronic heart failure: a clustered randomized controlled trial in Northwest Ethiopia
Dessie, G., Burrowes, S., Mulugeta, H., Haile, D. H., Negess, A., Jara, D., Alem, G., Tesfaye, B., Zeleke, H., Melesse, T. G., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02170-8 · Cited by 46
“Several risk factors such as ischemic heart disease, hypertension, smoking, obesity, diabetes increase heart failure incidence and severity [8].”
Background
Factors Associated With Hospital Readmission of Heart Failure Patients
Al-Tamimi, M. A.-A., Gillani, S. W., Alhakam, M. E. A., & Sam, K. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732760 · Cited by 42
Regenerative strategies for the consequences of myocardial infarction: Chronological indication and upcoming visions
Tajabadi, M., Orimi, H. G., Ramzgouyan, M. R., Nemati, A., Deravi, N., Beheshtizadeh, N., & Azami, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112584 · Cited by 46
Psychosocial Interventions for Patients With Heart Failure and Their Impact on Depression, Anxiety, Quality of Life, Morbidity, and Mortality: A Systematic Review and Meta-Analysis
Chernoff, R. A., Messineo, G., Kim, S., Pizano, D. R., Korouri, S., Danovitch, I., & IsHak, W. W. (2022) · Psychosomatic Medicine · doi:10.1097/psy.0000000000001073 · Cited by 42
“The costs of HF in 2012 were estimated at more than $30 billion in the United States, including the cost of health care services, medications, and missed days of work (1,3).”
BackgroundInfluential
Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
Butler, J., Stebbins, A., Melenovský, V., Sweitzer, N., Cowie, M., Stehlik, J., Khan, M. S., Blaustein, R. O., Ezekowitz, J., Hernandez, A., et al. (2022) · Circulation: Heart Failure · doi:10.1161/circheartfailure.121.009337 · Cited by 36
Performance of multilabel machine learning models and risk stratification schemas for predicting stroke and bleeding risk in patients with non-valvular atrial fibrillation
Lü, J., Hutchens, R., Hung, J., Bennamoun, M., McQuillan, B., Briffa, T. G., Sohel, F. A., Murray, K., Stewart, J. E., Chow, B. J. W., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106126 · Cited by 43
PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial
Kim, K., Kim, H., Hwang, I., Cho, H., Je, N., Kwon, O.-M., Choi, S., Lee, S., Kim, Y.-J., & Sohn, D. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.03.018 · Cited by 43
Phenylacetylglutamine as a Risk Factor and Prognostic Indicator of Heart Failure
Zong, X., Fan, Q., Yang, Q., Pan, R., Zhuang, L., & Tao, R. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13989 · Cited by 44
“Despite advances in medications and treatment strategies for HF, it continues to affect 23 million worldwide and is considered a major public health issue.(1) The pathogenesis of HF is very complex, at least including metabolic abnormalities, inflammation, immune system activation, and gut microbiota imbalance.”
Background
Smad3 Couples Pak1 With the Antihypertrophic Pathway Through the E3 Ubiquitin Ligase, Fbxo32
Tsui, H., Zi, M., Wang, S., Chowdhury, S. K., Prehar, S., Liang, Q., Cartwright, E. J., Lei, M., Liu, W., & Wang, X. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06068 · Cited by 42
“1176 Pathological cardiac hypertrophic growth is associated with many forms of heart disease, including ischemic disease, hypertension, myocardial infarction, and valvular disease, leading to eventual heart failure; 23 million people are affected worldwide.(1) The duration for progression from pathological hypertrophy…”
Background
Socioeconomic Inequalities in Heart Failure
Diaz‐Toro, F., Verdejo, H., & Castro, P. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.07.012 · Cited by 44
Diastolic Heart Failure: Progress, Treatment Challenges, and Prevention
Wood, P., Piran, S., & Liu, P. P. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.02.008 · Cited by 41
Pioglitazone Protected against Cardiac Hypertrophy via Inhibiting AKT/GSK3βand MAPK Signaling Pathways
Wei, W., Ma, Z., Xu, S., Zhang, N., & Tang, Q. (2016) · PPAR Research · doi:10.1155/2016/9174190 · Cited by 41
Salvianolic Acid B Alleviates Heart Failure by Inactivating ERK1/2/GATA4 Signaling Pathway after Pressure Overload in Mice
Yu, J., Chen, R., Tan, Y., Wu, J., Qi, J., Zhang, M., & Gu, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166560 · Cited by 41
Stem cell therapy in heart failure: Where do we stand today?
Nair, N., & Góngora, E. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.003 · Cited by 43
Ubiquitin C-terminal hydrolase L1 (UCHL1) regulates post-myocardial infarction cardiac fibrosis through glucose-regulated protein of 78 kDa (GRP78)
Lei, Q., Yi, T., Li, H., Yan, Z., Lv, Z., Li, G., & Wang, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-67746-4 · Cited by 41
Usefulness of heart rhythm complexity in heart failure detection and diagnosis
Tsai, C., Ma, H., Lin, Y.-T., Hung, C., Huang, S.-H., Chuang, B.-L., Lin, C., Lo, M., Peng, C., & Lin, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-71909-8 · Cited by 41
Incorporating Patients With Chronic Heart Failure Into Outpatient Cardiac Rehabilitation
Keteyian, S. J., Squires, R. W., Ades, P. A., & Thomas, R. J. (2014) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000073 · Cited by 40
The pathobiology of acute coronary syndromes: clinical implications and central role of the mitochondria.
Buja, L. M. (2013) · Europe PMC (PubMed Central) · Cited by 40
Inhibition of Hypertrophy, Per Se, May Not Be a Good Therapeutic Strategy in Ventricular Pressure Overload: Other Approaches Could Be More Beneficial
Crozatier, B., & Ventura‐Clapier, R. (2015) · Circulation · doi:10.1161/circulationaha.114.013895 · Cited by 40
“function is less decreased in women because they develop heart failure with preserved ejection fraction.(51) In that”
Background
TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure
Novoyatleva, T., Sajjad, A., & Engel, F. B. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00050 · Cited by 40
“However, despite these advances, the prevalence of heart failure has increased in the last decades, remaining one of the leading causes of death worldwide (10, 11).”
Background
Tailored educational supportive care programme on sleep quality and psychological distress in patients with heart failure: A randomised controlled trial
Chang, Y.-L., Chiou, A., Cheng, S., & Lin, K. (2016) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2016.07.002 · Cited by 40
The activation of the kynurenine pathway in a rat model with renovascular hypertension
Bartosiewicz, J., Kaminski, T. W., Pawlak, K., Karbowska, M., Tankiewicz‐Kwedlo, A., & Pawlak, D. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217693114 · Cited by 40
“Disturbances of renin–angiotensin–aldosterone (RAA) system seem to be the main cause of renovascular hypertension, which is still an unresolved medical problem that leads to increased mortality and morbidity.(1) The results of the present study shed new light on the pathophysiology underlying that abnormality and indi…”
BackgroundResult
Trypanosoma cruzi reservoir—triatomine vector co-occurrence networks reveal meta-community effects by synanthropic mammals on geographic dispersal
Ibarra-Cerdeña, C. N., Valiente‐Banuet, L., Sánchez-Cordero, V. M., Stephens, C. R., & Ramsey, J. M. (2017) · PeerJ · doi:10.7717/peerj.3152 · Cited by 40
Seasonal variation in hospitalization outcomes in patients admitted for heart failure in the United States
Akintoye, E. O., Briasoulis, Α., Egbe, A. C., Adegbala, O. M., Alliu, S., Sheikh, M. A., Singh, M., Ahmed, A., Mallikethi‐Reddy, S., & Levine, D. (2017) · Clinical Cardiology · doi:10.1002/clc.22784 · Cited by 40
“With an estimated prevalence of more than 5.7 million, heart failure (HF) continues to pose a significant public health challenge as the leading cause of 30-day hospital readmissions in the United States.1,2 By 2030, the American Heart Association has projected that the prevalence of HF will be >8 million, and the est…”
BackgroundInfluential
Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor
Becher, P. M., Hinrichs, S., Fluschnik, N., Hennigs, J. K., Klingel, K., Blankenberg, S., Westermann, D., & Lindner, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193844 · Cited by 40
Serum chloride as a novel marker for adding prognostic information of mortality in chronic heart failure
Zhang, Y., Peng, R., Li, X., Yu, J., Chen, X., & Zhou, Z. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.04.028 · Cited by 40
LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model
Chang, P., Lin, S., Chu, Y., Wo, H.-T., Lee, H.-L., Huang, Y.-C., Wen, M., & Chou, C. (2019) · Cardiovascular Therapeutics · doi:10.1155/2019/6032631 · Cited by 40
“8 million in the United States and over 23 million worldwide [1].”
Background
Selenium supplementation protects against oxidative stress-induced cardiomyocyte cell cycle arrest through activation of PI3K/AKT
Sun, W., Zhu, J., Li, S., Tang, C., Zhao, Q., & Zhang, J. (2020) · Metallomics · doi:10.1039/d0mt00225a · Cited by 41
Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study
Eckhardt, C. M., Balte, P., Barr, R. G., Bertoni, A. G., Bhatt, S. P., Cuttica, M. J., Cassano, P. A., Chaves, P. H. M., Couper, D. J., Jacobs, D. R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac205 · Cited by 42
Shengmai (a traditional Chinese herbal medicine) for heart failure
Zhou, Q., Qin, W., Liu, S.-B., Kwong, J. S., Zhou, J., & Chen, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005052.pub5 · Cited by 40
Retracted
Heme oxygenase-1: an emerging therapeutic target to curb cardiac pathology
Czibik, G., Dérumeaux, G., Sawaki, D., Valen, G., & Motterlini, R. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0450-9 · Cited by 40
“Irrespective of the aetiology and despite the best currently available treatment protocols, annual mortality of heart failure remains as high as 10 % [20].”
Background
Increased visit-to-visit blood pressure variability is associated with worse cardiovascular outcomes in low ejection fraction heart failure patients: Insights from the HEAAL study
Rossignol, P., Girerd, N., Gregory, D., Massaro, J. M., Konstam, M. A., & Zannad, F. M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.169 · Cited by 39
Prognosis after a first hospitalisation for acute myocardial infarction and congestive heart failure by country of birth
van Oeffelen, A. A. M., Agyemang, C. O., Stronks, K., Bots, M. L., & Vaartjes, I. C. H. (2014) · Heart · doi:10.1136/heartjnl-2013-305444 · Cited by 39
Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension
Gyöngyösi, M., Pávó, N., Lukovic, D., Zlabinger, K., Spannbauer, A., Traxler, D., Goliasch, G., Mandic, L., Bergler-Klein, J. K., Gugerell, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1299-0 · Cited by 39
“An increasing disease burden is attributed to patients with a phenotype cluster of adiposity, hyperlipidemia, and diabetes [2].”
A personalized, multiomics approach identifies genes involved in cardiac hypertrophy and heart failure
Santolini, M., Romay, M. C., Yukhtman, C., Rau, C. D., Ren, S. V., Saucerman, J. J., Wang, J., Weiss, J. N., Wang, Y., Lusis, A. J., et al. (2018) · npj Systems Biology and Applications · doi:10.1038/s41540-018-0046-3 · Cited by 38
“Heart failure (HF) is a well-studied example of a genetically complex disease involving multiple processes that eventually lead to a common phenotype of abnormal ventricular function and cardiac hypertrophy.(2) Numerous studies have attempted to pinpoint differentially expressed genes (DEGs) to find biomarkers for the…”
Background
Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19
Vasquez, C. R., Gupta, S., Miano, T. A., Roche, M., Hsu, J. Y., Yang, W. C., Holena, D. N., Reilly, J. P., Schrauben, S. J., Leaf, D. E., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.04.062 · Cited by 38
Research progress of Nedd4L in cardiovascular diseases
Li, M., Sun, G., Wang, P., Wang, W., Cao, K., Song, C., Sun, Y., Zhang, Y., & Zhang, N. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01017-1 · Cited by 38
Epi-Drugs in Heart Failure
Gorica, E., Mohammed, S. A., Ambrosini, S., Calderone, V., Costantino, S., & Paneni, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.923014 · Cited by 39
Comparative analysis of biochemical parameters in diabetic and non-diabetic acute myocardial infarction patients
Ali, F., Naqvi, S. A. S., Bismillah, M., & Wajid, N. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2015.09.026 · Cited by 39
The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective
Hayward, C., Banner, N. R., Morley-Smith, A. C., Lyon, A. R., & Harding, S. E. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.018 · Cited by 36
Quality of life and palliative care needs of elderly patients with advanced heart failure.
Chan, H. Y. L., Yu, D. S. F., Leung, D. Y. P., Chan, A. W. K., & Hui, E. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.05.016 · Cited by 38
Human iPS cell-derived engineered heart tissue does not affect ventricular arrhythmias in a guinea pig cryo-injury model
Pecha, S., Yorgan, K., Röhl, M., Geertz, B., Hansen, A., Weinberger, F., Sehner, S., Ehmke, H., Reichenspurner, H. C., Eschenhagen, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46409-z · Cited by 41
Efficacy of epicardial implantation of acellular chitosan hydrogels in ischemic and nonischemic heart failure: impact of the acetylation degree of chitosan
Domengé, O., Ragot, H., Deloux, R., Crépet, A., Revet, G., Boitard, S. E., Simon, A., Mougenot, N., David, L., Delair, T., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.10.045 · Cited by 38
Predicting The Risk Of Heart Disease Using Advanced Machine Learning Approach
Waigi, R., Choudhary, S., Fulzele, P. R., & Mishra, G. (2020) · European Journal of Molecular & Clinical Medicine · Cited by 37
Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach
Sukumar, S., Orkaby, A. R., Schwartz, J. B., Marcum, Z. A., Januzzi, J. L., Vaduganathan, M., & Warraich, H. J. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00559-w · Cited by 40
DNA repair in cardiomyocytes is critical for maintaining cardiac function in mice
de Boer, M., Hekkert, M. T. L., Chang, J., van Thiel, B. S., Martens, L., Bos, M. M., de Kleijnen, M. G. J., Ridwan, Y. R., Octavia, Y., van Deel, E. D., et al. (2023) · Aging Cell · doi:10.1111/acel.13768 · Cited by 36
Cardiac myosin-binding protein-C is a critical mediator of diastolic function
Tong, C. W.-C., Nair, N., Doersch, K., Liu, Y., & Rosas, P. C. (2014) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1442-1 · Cited by 36
“It has an estimated global prevalence of 23 M [4].”
Background
Targeting the Wnt/frizzled signaling pathway after myocardial infarction: A new tool in the therapeutic toolbox?
Daskalopoulos, E. P., Hermans, K. C. M., Janssen, B. J., & Blankesteijn, W. M. (2012) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.09.010 · Cited by 37
“The number of HF patients worldwide is estimated to be more than 23 million people (Bui et al., 2011) and about 6–10 % of people over 65 years of age suffer from it (McMurray and Pfeffer, 2005), establishing it as a major health problem.”
Background
Automatic SVM classification of sudden cardiac death and pump failure death from autonomic and repolarization ECG markers
Ramírez, J., Monasterio, V., Mincholé, A., Llamedo, M., Lenis, G., Cygankiewicz, I., de Luna, A. B., Malík, M., Martínez, J. P., Laguna, P., et al. (2015) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2015.04.002 · Cited by 37
“Mortality rate in patients with chronic heart failure (CHF) remains high despite advancement in modern treatment [1].”
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice
Alla, J. A., Grämer, M., Fu, X., & Quitterer, U. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.702688 · Cited by 38
“The causes of heart failure are complex with ischemic heart disease being the most frequently associated condition (2).”
Background
Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation
Verschure, D. O., van Eck‐Smit, B. L. F., Somsen, G. A., Knol, R. J. J., & Verberne, H. J. (2016) · Netherlands Heart Journal · doi:10.1007/s12471-016-0902-y · Cited by 37
“Heart failure (HF) is a life-threatening disease affecting approximately 26 million people worldwide [1].”
Background
Spirituality: A Panacea for Patients Coping with Heart Failure.
Shahrbabaki, P. M., Nouhi, E., Kazemi, M., & Ahmadi, F. (2017) · Europe PMC (PubMed Central) · Cited by 37
Novel Protective Role of Myeloid Differentiation 1 in Pathological Cardiac Remodelling
Xiong, X., Liu, Y., Mei, Y., Peng, J., Wang, Z., Kong, B., Zhong, P., Xiong, L., Quan, D., Li, Q., et al. (2017) · Scientific Reports · doi:10.1038/srep41857 · Cited by 36
The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction
Dolinsky, V. W. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0316 · Cited by 37
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines
Ramos, I. C., Versteegh, M., de Boer, R. A., Koenders, J., Linssen, G. C. M., Meeder, J. G., & Mölken, M. R. (2017) · Value in Health · doi:10.1016/j.jval.2017.05.013 · Cited by 37
Psychometric characteristics of the mutuality scale in heart failure patients and caregivers
Dellafiore, F., Buck, H. G., Pucciarelli, G., Barbaranelli, C., Paturzo, M., Alvaro, R., & Vellone, E. (2018) · Heart & Lung · doi:10.1016/j.hrtlng.2018.05.018 · Cited by 37
A prospective evaluation of telemonitoring use by seniors with chronic heart failure: Adoption, self-care, and empowerment
Jaana, M., Sherrard, H., & Paré, G. (2018) · Health Informatics Journal · doi:10.1177/1460458218799458 · Cited by 37
Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Atherosclerosis)
Watson, M., Dardari, Z., Kianoush, S., Hall, M. E., DeFilippis, A. P., Keith, R. J., Benjamin, E. J., Rodríguez, C. J., Bhatnagar, A., Lima, J. A. C., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.03.015 · Cited by 39
A new technique for the prediction of heart failure risk driven by hierarchical neighborhood component-based learning and adaptive multi-layer networks
Samuel, O. W., Yang, B., Geng, Y., Asogbon, M. G., Pirbhulal, S., Mzurikwao, D., Idowu, O. P., Ogundele, T. J., Li, X., Chen, S., et al. (2019) · Future Generation Computer Systems · doi:10.1016/j.future.2019.10.034 · Cited by 39
MSC-Encapsulating in Situ Cross-Linkable Gelatin Hydrogels To Promote Myocardial Repair
Kim, C. W., Kim, C. J., Park, E., Ryu, S. B., Lee, Y., Kim, E., Kang, K., Lee, K. Y., Choo, E. H., Hwang, B., et al. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01215 · Cited by 37
Clinical impact of compound sarcopenia in hospitalized older adult patients with heart failure
Attaway, A. H., Bellar, A., Dieye, F., Wajda, D. A., Welch, N., & Dasarathy, S. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17108 · Cited by 37
Activation of transient receptor potential vanilloid 4 is involved in pressure overload-induced cardiac hypertrophy
Zou, Y., Zhang, M., Wu, Q., Zhao, N., Chen, M., Yang, C. B., Du, Y., & Han, B. (2022) · eLife · doi:10.7554/elife.74519 · Cited by 37
Regional Variation in Mortality, Length of Stay, Cost, and Discharge Disposition Among Patients Admitted for Heart Failure in the United States
Akintoye, E. O., Briasoulis, Α., Egbe, A. C., Adegbala, O. M., Sheikh, M. A., Singh, M., Alliu, S., Ahmed, A., Asleh, R., Kushwaha, S. S., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.058 · Cited by 37
Urinary Cadmium and Incident Heart Failure
Sears, C. G., Eliot, M., Raaschou‐Nielsen, O., Poulsen, A. H., Harrington, J. M., Howe, C. J., James, K. A., Roswall, N., Overvad, K., Tjønneland, A. M., et al. (2021) · Epidemiology · doi:10.1097/ede.0000000000001446 · Cited by 37
Heart failure after conventional metal-on-metal hip replacements
Gillam, M., Pratt, N. L., Inacio, M. C. S., Roughead, E. E., Shakib, S., Nicholls, S. J., & Graves, S. E. (2016) · Acta Orthopaedica · doi:10.1080/17453674.2016.1246276 · Cited by 36
Heart failure in numbers: Estimates for the 21st century in Portugal
Fonseca, C., Brás, D., Araújo, I., & Ceia, F. (2018) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2017.11.017 · Cited by 36
“However, due to differences in populations and in the criteria used for both defining and diagnosing HF, the results obtained are divergent and there is a lack of agreement on estimates of prevalence and incidence of the syndrome.(1,4) Nevertheless, the prevalence of HF in developed countries is estimated to be around…”
Background
Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction
Pavlovic, A. S., Polovina, M. M., Ristić, A. D., Seferović, J. P., Veljić, I., Simeunović, D. S., Milinković, I., Krljanać, G., Ašanin, M., Ostric, I., et al. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318807767 · Cited by 36
Self-care confidence mediates self-care maintenance and management in patients with heart failure
Massouh, A. R., Skouri, H. N., Cook, P. F., Abu‐Saad, H. H., Khoury, M., & Meek, P. (2019) · Heart & Lung · doi:10.1016/j.hrtlng.2019.07.008 · Cited by 36
Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices
den Exter, P. L., Beeres, S. L. M. A., Eikenboom, J. C. J., Klok, F. A., & Huisman, M. V. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1773803 · Cited by 36
Bioactive decellularized cardiac extracellular matrix-based hydrogel as a sustained-release platform for human adipose tissue-derived stromal cell-secreted factors
Liguori, T. T. A., Liguori, G. R., van Dongen, J. A., Moreira, L. F. P., & Harmsen, M. C. (2020) · Biomedical Materials · doi:10.1088/1748-605x/abcff9 · Cited by 35
Model-based comorbidity clusters in patients with heart failure: association with clinical outcomes and healthcare utilization
Gulea, C., Zakeri, R., & Quint, J. K. (2021) · BMC Medicine · doi:10.1186/s12916-020-01881-7 · Cited by 36
Carbonic anhydrase 2 and 3 as risk biomarkers for dilated cardiomyopathy associated heart failure
Su, H., Hu, K., Liu, Z., Chen, K., & Xu, J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-3561 · Cited by 36
Sleep quality and associated factors among patients with chronic heart failure in Iran.
Moradi, M., Mehrdad, N., Nikpour, S., Haghani, H., Aalaa, M., Sanjari, M., & Sharifi, F. (2014) · PubMed Central · Cited by 36
National Patterns of Heart Failure Hospitalizations and Mortality by Sex and Age
Rodríguez, F., Wang, Y., Johnson, C. E., & Foody, J. M. (2013) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.05.016 · Cited by 36
“This finding is likely due to different disease pathogenesis in women, prevalent risk factors, and treatment patterns.(16) Evidence-based treatment strategies for patients with diastolic dysfunction are lacking, and this may result in higher rates of hospitalizations for symptomatic management.”
Background
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews
Karakasis, P., Pamporis, K., Stachteas, P., Patoulias, D., Bougioukas, K. I., & Fragakis, N. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10324-3 · Cited by 35
Assessment and management of heart failure in patients with chronic kidney disease
Guaricci, A. I., Sturdà, F., Russo, R., Basile, P., Baggiano, A., Mushtaq, S., Fusini, L., Fazzari, F., Bertandino, F., Monitillo, F., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10346-x · Cited by 39
“The management of heart failure (HF) has greatly improved during the recent years, but the prognosis remains poor [1].”
Background
Intrinsic and Extrinsic Contributors to the Cardiac Benefits of Exercise
Hastings, M. H., Castro, C., Freeman, R., Kadir, A. A., Lerchenmüller, C., Li, H., Rhee, J., Roh, J. D., Roh, K., Singh, A. P., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.07.011 · Cited by 36
Explainable AI assisted heart disease diagnosis through effective feature engineering and stacked ensemble learning
Ghose, P., Oliullah, K., Mahbub, M. K., Biswas, M., Uddin, K. N., & Jamil, H. M. (2024) · Expert Systems with Applications · doi:10.1016/j.eswa.2024.125928 · Cited by 35
Amyloid-β and heart failure in Alzheimer’s disease: the new vistas
Al-Kuraishy, H. M., Sulaiman, G. M., Mohammed, H. A., Mohammed, S. G., Al-Gareeb, A. I., Albuhadily, A. K., Dawood, R. A., Ali, A. A., & Abu-Alghayth, M. H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1494101 · Cited by 37
Early Changes in Cytochrome P450s and Their Associated Arachidonic Acid Metabolites Play a Crucial Role in the Initiation of Cardiac Hypertrophy Induced by Isoproterenol
Althurwi, H. N., Maayah, Z. H., Elshenawy, O. H., & El‐Kadi, A. O. S. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063776 · Cited by 35
“In North America, the total inpatient care cost for CVD is ;$91 billion (Lloyd-Jones et al., 2009; Conference Board of Canada, 2010).”
Background
Stem Cell Factor Gene Transfer Improves Cardiac Function After Myocardial Infarction in Swine
Ishikawa, K., Fish, K. M., Agüero, J., Yaniz‐Galende, E., Jeong, D., Kho, C., Tilemann, L. M., Fish, L. A., Liang, L., Eltoukhy, A. A., et al. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001711 · Cited by 36
Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials
Bonsu, K. O., Reidpath, D. D., & Kadirvelu, A. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6636-z · Cited by 35
“The world's aging population and the epidemiological transition will only increase the burden in the foreseeable future [1, 2].”
Background
The heart failure pandemic: The clinical and economic burden in Greece
Stafylas, P. C., Farmakis, D. T., Kourlaba, G., Giamouzis, G., Tsarouhas, K., Maniadakis, N., & Parissis, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.042 · Cited by 35
Progression of Coronary Artery Calcium and Incident Heart Failure: The Multi‐Ethnic Study of Atherosclerosis
Bakhshi, H., Ambale‐Venkatesh, B., Yang, X., Ostovaneh, M. R., Wu, C. O., Budoff, M. J., Bahrami, H., Wong, N. D., Bluemke, D. A., & Lima, J. A. C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005253 · Cited by 35
“7 million Americans suffer from HF,(1) and each year more than 550 000 new cases of HF are diagnosed.(4) The most common cause of HF in the United States is coronary artery disease (CAD).”
Background
Association between chemerin, omentin-1 and risk of heart failure in the population-based EPIC-Potsdam study
Menzel, J., di Giuseppe, R., Biemann, R., Wittenbecher, C., Aleksandrova, K., Eichelmann, F., Fritsche, A., Schulze, M. B., Boeing, H., Isermann, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14518-2 · Cited by 35
Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and Functionality After Pressure Overload Injury in Mice
Witsch, T., Martinod, K., Sorvillo, N., Portier, I., Meyer, S. F. D., & Wagner, D. D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007004 · Cited by 35
“During a life span, fibrotic tissue accumulates within the myocardium, increasing the incidence of congestive heart failure.(1) Although aging itself can be viewed as an inflammatory process,(21) chronic or repeated injuries to the heart, as with viral myocarditis, may contribute to this phenomenon.”
Background
Arrhythmogenic mechanisms of obstructive sleep apnea in heart failure patients
Chadda, K. R., Fazmin, I. T., Ahmad, S., Valli, H., Edling, C. E., Huang, C. L.-H., & Jeevaratnam, K. (2018) · SLEEP · doi:10.1093/sleep/zsy136 · Cited by 41
High-Intensity Interval Training is Associated with Improved Long-Term Survival in Heart Failure Patients
Hsu, C., Fu, T., Yuan, S., Wang, C., Liu, M., Shyu, Y., Cherng, W., & Wang, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030409 · Cited by 37
“Population surveys have estimated HF prevalence at 2–3% in Western societies [3] and 1.”
Background
Assessment of Heart Failure Patients’ Interest in Mobile Health Apps for Self-Care: Survey Study
Sohn, A., Speier, W. F., Lan, E. H., Aoki, K., Fonarow, G. C., Ong, M. K., & Arnold, C. W. (2019) · JMIR Cardio · doi:10.2196/14332 · Cited by 35
Self-citation
miRNAs in the development of left ventricular remodeling and post-myocardial infarction heart failure
Sygitowicz, G., Maciejak, A., & Sitkiewicz, D. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15137 · Cited by 35
Liver enzyme variability and risk of heart disease and mortality: A nationwide population‐based study
Cho, E. J., Han, K., Lee, S., Shin, D. W., & Yu, S. J. (2020) · Liver International · doi:10.1111/liv.14432 · Cited by 35
“5-23), overweight (23-25), obese (25-30) and severely obese (≥30-35), according to Asian obesity criteria.”
Background
Early Detection of Heart Failure With Reduced Ejection Fraction Using Perioperative Data Among Noncardiac Surgical Patients: A Machine-Learning Approach
Mathis, M. R., Engoren, M., Joo, H., Maile, M. D., Aaronson, K. D., Burns, M. L., Sjoding, M. W., Douville, N. J., Janda, A. M., Hu, Y., et al. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004630 · Cited by 35
Living with Chronic Heart Failure: Exploring Patient, Informal Caregiver, and Healthcare Professional Perceptions
Sedlar, N., Lainščak, M., & Farkaš, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17082666 · Cited by 35
Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
Nielsen, E. E., Feinberg, J. B., Bu, F.-L., Olsen, M. H., Raymond, I. E., Steensgaard-Hansen, F., & Jakobsen, J. C. (2020) · Open Heart · doi:10.1136/openhrt-2020-001294 · Cited by 39
Identification of dynamic RNA-binding proteins uncovers a Cpeb4-controlled regulatory cascade during pathological cell growth of cardiomyocytes
Riechert, E., Kmietczyk, V., Stein, F., Schwarzl, T., Sekaran, T., Jürgensen, L., Kamuf‐Schenk, V., Varma, E., Hofmann, C. P., Rettel, M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109100 · Cited by 35
sST2 and Heart Failure—Clinical Utility and Prognosis
Dudek, M., Kałużna‐Oleksy, M., Migaj, J., Sawczak, F., Krysztofiak, H., Lesiak, M., & Straburzyńska‐Migaj, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093136 · Cited by 39
Cardiac tissue engineering: renewing the arsenal for the battle against heart disease
Georgiadis, V., Knight, R. A., Jayasinghe, S. N., & Stephanou, A. (2013) · Integrative Biology · doi:10.1039/c3ib40097b · Cited by 33

Authors: Bui, A. L., Horwich, T. B., & Fonarow, G. C.
Affiliations: University of California, Los Angeles (US)
Corresponding author: Fonarow, Gregg C.
ORCID: Horwich, Tamara B.
Fonarow, Gregg C.
Venue: Nature Reviews Cardiology
Publisher: Springer Science and Business Media LLC
Published: 2010-11-09
Volume: 8
Issue: 1
Pages: 30-41
ISSN: 1759-5002 (ISSN-L)
1759-5010
DOI: 10.1038/nrcardio.2010.165
PMC: PMC3033496
OpenAlex: W1992644002
Cited by: 2,077
References: 144
Citations by year: 2026: 48 · 2025: 91 · 2024: 126 · 2023: 158 · 2022: 173 · 2021: 186 · 2020: 209 · 2019: 169 · 2018: 191 · 2017: 211 · 2016: 174 · 2015: 121 · 2014: 91 · 2013: 60 · 2012: 46
FWCI: 6.84
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Cardiology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Heart Failure Society of America
Ahmanson Foundation
National Institutes of Health (5k23hl085097-04)
National Heart, Lung, and Blood Institute (1K23HL085097, K23 HL085097, T32HL007895)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords: heart failure, heart failure epidemiology, heart failure risk factors, heart failure prevalence, heart failure mortality, health care costs, ischemic heart disease, hypertension, smoking, obesity, diabetes mellitus
MeSH terms: Adult, Aged, Female, Heart Failure, Humans, Male, Middle Aged, Prognosis, Risk Factors, Time Factors, Incidence, Prevalence, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology and risk profile of heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks